BioNTech Pulls the Plug on Pandemic-Era Factories in a Cost-Driven Pivot to Oncology

BioNTech will shut three German sites and its Singapore facility, affecting 1,800 jobs, after failing to find buyers for its pandemic-era vaccine capacity.

BioNTech is closing the chapter on its pandemic manufacturing empire. The Mainz-based biotech confirmed it will wind down production at three German sites — Idar-Oberstein, Marburg and Tübingen — along with its Singapore facility, after an extensive search for buyers came up empty. The decision affects roughly 1,800 employees worldwide, about a quarter of the company's total workforce.

The stock traded at EUR 86.25 on the day, down 1.1%, leaving it 18% below its 52-week high of EUR 105.80. The company's market capitalization currently stands at EUR 21.79 billion.

A Capacity Hangover That Couldn't Be Sold

The Marburg plant, acquired from Novartis in 2020, was built for an annual output of up to 750 million vaccine doses. That scale no longer matches reality. With COVID-19 vaccine revenue evaporating and global mRNA manufacturing capacity now in overwhelming surplus, Reuters reported that a broad sales process simply ran aground on market conditions. No buyer stepped forward.

The retreat unfolds in stages. Tübingen's production line is set to halt at the end of 2027, Marburg follows in early 2028, and Idar-Oberstein wraps up at the end of 2028. Management negotiated socially compatible layoffs and severance packages with the works council, but local backlash has been sharp. Tübingen's mayor, Boris Palmer, publicly questioned BioNTech's claim that no buyer could be found, suggesting the closure had been planned from the start. CureVac founder Ingmar Hoerr also weighed in from Tübingen, accusing BioNTech of failing to follow through on a promised joint venture.

The Numbers Behind the Retreat

The financial picture explains the urgency. In the first quarter of 2026, BioNTech generated just EUR 118.1 million in revenue, down from EUR 182.8 million a year earlier. The net loss for the first half totaled EUR 1.35 billion, as COVID-19 vaccine income collapsed while research and development spending continued unabated. Carrying massive idle production capacity under those conditions had become untenable.

BioNTech is handing off its remaining COVID-19 vaccine production entirely to partner Pfizer. The logic is straightforward: why subsidize expensive in-house manufacturing lines when a partner can capture the scale effects more efficiently?

EUR 500 Million in Annual Savings to Fund the Pipeline

The restructuring is expected to deliver recurring annual savings of roughly EUR 500 million by 2029. That capital is earmarked for the company's core ambitions — cancer drugs, mRNA immunotherapies and antibody-drug conjugates. BioNTech aims to secure regulatory approvals for several oncology candidates by 2030, betting that its technology platform can produce viable therapies well beyond vaccines.

A leadership transition is unfolding alongside the operational overhaul. Founders U?ur ?ahin and Özlem Türeci are stepping back from day-to-day management to launch a new venture with Arife, though they will remain as advisers and shareholders. ?ahin intends to leave BioNTech by the end of 2026 to build a new mRNA company together with Türeci. Guido Oelkers is set to take over as CEO no later than February 1, 2027.

Legal Clouds and the Road Ahead

Adding to the pressure, a patent dispute in the United States is tying up resources. A Bayer subsidiary has accused manufacturers of using protected mRNA technologies in their vaccines without authorization. No ruling on actual infringement has been issued yet, but the proceedings continue to demand attention.

For investors, the calculus tilts toward the medium term. A leaner cost base and a sharper focus on oncology offer the prospect of a more disciplined operation, even if the transition — stretching through the plant closures from late 2027 onward — will require patience.